SONN Stock News: Sonnet BioTherapeutics plummets by nearly 20% after medical community rebukes FDA

NASDA:SONN shares were sold off on Tuesday after a near 70% spike to start the week.
Scientists, World Health Organization, voice scepticism about the proficiency of convalescent plasma therapy to treat COVID-19.

Stocks Reporter FXStreet

It has been an interesting start to the week for investors of Sonnet BioTherapeutics (NASDAQ:SONN). The announcement by the FDA over the weekend about a shift in focus towards convalescent plasma therapies as a viable coronavirus treatment sent shockwaves through the biotech industry. Sonnet shares were up nearly 70% pre-market on Monday and peaked at $4.32 before crashing back down to earth on Tuesday. The stock price of Sonnet has dropped by over 70% during the past year and is well over 90% below its 52-week high of $54.60.

The FDA is under fire after echoing President Donald Trump’s sentient that convalescent plasma therapy would save countless lives. Within 24 hours of the announcement, members of the scientific community, including the chief scientist for the World Health Organization questioned the FDA and even went as far as to say that the claims were “very low-quality evidence” and that convalescent plasma transfusion for COVID-19 is still “an experimental treatment”. Even Dr. Anthony Fauci – a member of the White House’s coronavirus task force – had his own reservations about how accurate the treatment statistics that the FDA provided truly are.

SONN Stock Price

While the rebuking of the FDA’s claims of the efficacy of convalescent plasma-based treatments should not be ignored, it may not signal the end of Sonnet’s bid to produce an effective coronavirus treatment. Industry rivals ADMA Biologics Inc (NASDAQ:ADMA) and T2 Biosystems Inc (NASDAQ:TTOO) were also in the red on Tuesday – making it clear that investors are abandoning the plasma therapy industry almost as quickly as they entered it.

Author

Stocks Reporter

FXStreet

GBP/USD: Downward-sloping trendline near 1.3470 remains key barrier

The British pound faces selling pressure against its major currency peers, trading 0.1% lower at around 1.3420 against the US Dollar during the European trading session on Tuesday.

EUR/USD flatlines above 1.1500, awaits US jobs data

EUR/USD holds steady around 1.1505 in European trading hours on Tuesday. Markets remain cautious ahead of a slew of US jobs data, starting with the JOLTS Job Openings Survey later today. However, the downside appears capped by hot Eurozone inflation in July, bolstering the case for a European Central Bank rate hike at the next meeting.

Gold holds steady above $4,050; hawkish Fed bets favor bearish traders

Gold remains confined in a range below the $4,100 mark through the early European session as traders opt to wait for further developments surrounding the Middle East crisis. Meanwhile, the uncertainty over US-Iran peace talks continues to act as a tailwind for the safe-haven US Dollar.

Aave: Bearish RSI divergence risks a 20% drop despite steady DeFi deposits

Aave (AAVE) extends a mild near-term recovery on Tuesday, holding above its 50-day Exponential Moving Average at $90.80. Aave protocol’s V3 deployment on Monad blockchain recorded over $500 million in deposits over the last month, reflecting increased user adoption.

US JOLTs report in focus

In the US, the June JOLTs report will be in the spotlight. Job openings have increased modestly this year, which has historically predicted rising wage cost pressures ahead. June trade balance data will also be released in the afternoon and the preliminary reading pointed towards a stable trade deficit from May. The Fed's Schmid (non-voter, hawk) will be on the wires overnight.

9-3: Is the Federal Reserve’s vote tally Warsh's new forward guidance?

The rate did not move. Neither did the statement, and that’s the more interesting fact. Set the July 29 Federal Open Market Committee (FOMC) statement beside the one issued on June 17, and the two documents are identical apart from a single verb and a paragraph at the bottom naming three dissenters.